Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.

Jian CuiTengteng YuRui LvJiahui LiuHuishou FanWenqiang YanJingyu XuChenxing DuShuhui DengWeiwei SuiMatthew HoYan XuKenneth C AndersonXifeng DongLugui QiuGang An

Published in: Therapeutic advances in medical oncology (2024)

These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.

Keyphrases

poor prognosis
long non coding rna
single molecule
multiple myeloma
cross sectional
newly diagnosed
energy transfer